Analysts predict that Unum Therapeutics Inc (NASDAQ:UMRX) will report earnings per share (EPS) of ($0.35) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Unum Therapeutics’ earnings, with estimates ranging from ($0.48) to ($0.26). Unum Therapeutics posted earnings of ($0.34) per share in the same quarter last year, which suggests a negative year over year growth rate of 2.9%. The business is expected to announce its next quarterly earnings results on Monday, November 11th.
On average, analysts expect that Unum Therapeutics will report full year earnings of ($1.30) per share for the current financial year, with EPS estimates ranging from ($1.42) to ($1.23). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.73) to ($0.91). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The company had revenue of $3.14 million during the quarter, compared to the consensus estimate of $3.10 million.
NASDAQ UMRX traded up $0.12 on Thursday, hitting $1.91. The stock had a trading volume of 6,452 shares, compared to its average volume of 202,508. Unum Therapeutics has a 52-week low of $1.75 and a 52-week high of $16.72. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $55.12 million, a P/E ratio of -1.37 and a beta of 1.38. The business has a 50-day moving average of $2.25.
Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new position in shares of Unum Therapeutics during the 1st quarter valued at $85,000. Acadian Asset Management LLC grew its holdings in shares of Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after purchasing an additional 18,717 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Unum Therapeutics by 251.5% during the 4th quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after purchasing an additional 33,091 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in shares of Unum Therapeutics by 7.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock valued at $242,000 after purchasing an additional 3,846 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Unum Therapeutics by 72.4% during the 4th quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock valued at $279,000 after purchasing an additional 26,742 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More: How to execute a trade ex-dividend strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.